Top Analysts Recommend 3 Biotech Stocks with Significant Upside Potential
Wall Street's top analysts have identified Pharvaris (PHVS) and Savara (SVRA) as strong buy opportunities in the biotech sector. Pharvaris, developing oral therapies for hereditary angioedema, carries an 85% upside potential according to unanimous Buy ratings from five analysts. H.C. Wainwright maintains a $60 price target.
Savara, focused on rare respiratory diseases, saw its price target raised to $11 from $8 by Citizens JMP. The clinical-stage biotech holds Buy ratings from five of six covering analysts. These picks emerge as investors increasingly favor high-growth healthcare plays amid market volatility.